Beijing Scitop Bio Tech Co Ltd (300858) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.024x

Based on the latest financial reports, Beijing Scitop Bio Tech Co Ltd (300858) has a cash flow conversion efficiency ratio of 0.024x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥44.72 Million ≈ $6.54 Million USD) by net assets (CN¥1.83 Billion ≈ $267.24 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Beijing Scitop Bio Tech Co Ltd (300858) total market value for the company's overall valuation and market capitalisation.

Beijing Scitop Bio Tech Co Ltd - Cash Flow Conversion Efficiency Trend (2015–2025)

This chart illustrates how Beijing Scitop Bio Tech Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Beijing Scitop Bio Tech Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Beijing Scitop Bio Tech Co Ltd ranked by their cash flow conversion efficiency. Explore cash flow quality index of Beijing Scitop Bio Tech Co Ltd to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
Guangdong Eastone Century Technology Co Ltd
SHE:300310
-0.086x
Vulcan Steel Ltd
AU:VSL
0.138x
Cheng Du Sheng Nuo Biotec Co. Ltd. A
SHG:688117
-0.021x
Soulbrain Holdings Co. Ltd
KQ:036830
0.005x
Guaranty Bancshares, Inc.
NYSE:GNTY
0.021x
Universal Health Realty Income Trust
NYSE:UHT
0.086x
Stark Technology Inc
TW:2480
0.235x
Heren Health Co Ltd
SHE:300550
0.006x

Annual Cash Flow Conversion Efficiency for Beijing Scitop Bio Tech Co Ltd (2015–2025)

The table below shows the annual cash flow conversion efficiency of Beijing Scitop Bio Tech Co Ltd from 2015 to 2025. View Beijing Scitop Bio Tech Co Ltd stock quote for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 CN¥1.84 Billion
≈ $269.66 Million
CN¥123.44 Million
≈ $18.06 Million
0.067x -15.65%
2024-12-31 CN¥1.79 Billion
≈ $261.87 Million
CN¥142.11 Million
≈ $20.80 Million
0.079x +28.30%
2023-12-31 CN¥1.73 Billion
≈ $253.59 Million
CN¥107.27 Million
≈ $15.70 Million
0.062x -29.26%
2022-12-31 CN¥1.70 Billion
≈ $248.26 Million
CN¥148.46 Million
≈ $21.72 Million
0.088x -23.23%
2021-12-31 CN¥967.40 Million
≈ $141.56 Million
CN¥110.27 Million
≈ $16.14 Million
0.114x +59.44%
2020-12-31 CN¥932.59 Million
≈ $136.47 Million
CN¥66.67 Million
≈ $9.76 Million
0.071x -70.91%
2019-12-31 CN¥399.83 Million
≈ $58.51 Million
CN¥98.27 Million
≈ $14.38 Million
0.246x -17.16%
2018-12-31 CN¥301.83 Million
≈ $44.17 Million
CN¥89.55 Million
≈ $13.10 Million
0.297x -0.72%
2017-12-31 CN¥281.09 Million
≈ $41.13 Million
CN¥84.00 Million
≈ $12.29 Million
0.299x +77.64%
2016-12-31 CN¥194.57 Million
≈ $28.47 Million
CN¥32.73 Million
≈ $4.79 Million
0.168x +229.95%
2015-12-31 CN¥52.67 Million
≈ $7.71 Million
CN¥2.69 Million
≈ $392.95K
0.051x --

About Beijing Scitop Bio Tech Co Ltd

SHE:300858 China Biotechnology
Market Cap
$553.30 Million
CN¥3.78 Billion CNY
Market Cap Rank
#11819 Global
#3394 in China
Share Price
CN¥14.35
Change (1 day)
+0.63%
52-Week Range
CN¥13.03 - CN¥25.45
All Time High
CN¥35.93
About

Beijing Scitop Bio-tech Co., Ltd. engages in the research, development, production, and sale of probiotic, postbiotics, and microecological preparations for animals and plants in China. It provides probiotic and postbiotics for gastrointestinal health, immune regulation, oral health, sleep aid and stress relief, women's health, slimming and fat reduction, kidney and liver protection, blood sugar … Read more